The startup has developed a kidney monitoring system that precisely measures urine volume and correlates it with vital signs to estimate renal perfusion. This technology enables early detection of acute kidney injury through a proprietary algorithm, helping medical professionals intervene before critical declines in kidney function occur.
Funding
$310K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute Kidney Injury (AKI) carries a high mortality rate, exceeding that of several major diseases combined. Early detection of AKI is challenging, often relying on infrequent manual monitoring and lagging indicators of kidney function. This delay hinders timely intervention and worsens patient outcomes.
Solution
Renalert is developing a real-time kidney monitoring system designed to detect Acute Kidney Stress and early declines in kidney function. The system precisely measures urine volume and correlates it with vital signs to estimate renal perfusion. By continuously monitoring these key indicators, the Renalert system aims to provide medical professionals with the data needed to intervene proactively, preventing needless deaths due to AKI. The core technology is a proprietary algorithm that analyzes the collected data to identify subtle changes indicative of kidney distress.
Target Audience
The primary target audience includes hospitals, intensive care units, and medical professionals focused on nephrology and critical care.
Features
- Real-time monitoring of urine volume
- Correlation of urine output with vital signs
- Estimation of renal perfusion
- Proprietary algorithm for early detection of Acute Kidney Stress